[ad_1]
Moderna has started testing an mRNA influenza vaccine in clinical trials, with the company announcing on Wednesday that the first participants have been assayed in the Phase 1/2 study. The vaccine, mRNA-1010, is Moderna’s first seasonal influenza vaccine candidate to enter clinical trials and will target influenza A H1n1, H3N2 and influenza B Yamagata and Victoria.
The company aims to enroll 180 participants aged 18 and over in the trial, and ultimately aims to study combination vaccines to target several respiratory viruses such as SARS-CoV-2 and RSV.
“We are delighted to have started this Phase 1/2 study of mRNA-1010, our first candidate vaccine against seasonal mRNA influenza to enter the clinic,” said Stéphane Bancel, CEO of Moderna, in a statement. Press. “Combination respiratory vaccines are an important pillar of our overall mRNA vaccine strategy. We believe the benefits of mRNA vaccines include the ability to combine different antigens to protect against multiple viruses and the ability to respond quickly to the assessment of respiratory viruses, such as influenza, SARS-CoV-2, and RSV. “
DELTA COVID-19 VARIANT NOW DOMINANT IN THE UNITED STATES, CDC PREDICTS
Traditionally, annual influenza vaccines have been between 40% and 60% effective, but newer mRNA-based COVID-19 vaccines have recorded rates of up to 90%. Moderna’s COVID-19 jab, in particular, saw 94.1% effectiveness in those who received two doses.
CLICK HERE FOR FULL CORONAVIRUS COVERAGE
“Our vision is to develop a combined mRNA vaccine so that people can be injected each fall for highly effective protection against the most problematic respiratory viruses,” Bancel said. “We look forward to advancing our core modality of prophylactic mRNA vaccines so that we can continue to make an impact on global public health. ”
[ad_2]
Source link